First patient dosed with PBA-0405
Pure Biologics announced on July 15, 2024 the dosing of the first patient was with the candidate PBA-0405 in a Phase 0 study. The first patient, diagnosed with head and neck squamous cell carcinoma [HNSCC], was recruited at the Louisiana State University Hospital in Shreveport. Intratumoral administration of PBA-0405 will provide data on the pharmacodynamics of PBA-0405 in form of biomarkers. The study is being conducted by Presage Biosciences, Inc.
Zermatt Consulting is proud to be part of this journey and is optimistic that PB-0405 will have positive outcomes in patient in the future.
Pure Biologics on LinkedIn: #drug #carcinoma #tumor #anticancer #development #cancer #therapy…
Pure Biologics is happy to announce that on July 15, 2024 the first patient was dosed with the #drug candidate PBA-0405 in a Phase 0 study. The patient…
Pure Biologics